⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25683324 | 0.92 | — | — | |
| SCHEMBL25257371 | 0.91 | CA14 (0.31) | — | |
| SCHEMBL25255776 | 0.86 | — | — | |
| SCHEMBL25272070 | 0.85 | SSTR4 (0.30) | — | |
| SCHEMBL25217965 | 0.84 | CCR6 (0.37) | — | |
| SCHEMBL25212608 | 0.84 | — | — | |
| SCHEMBL25683350 | 0.84 | CA14 (0.31) | — | |
| SCHEMBL25683482 | 0.83 | — | — | |
| SCHEMBL25211816 | 0.81 | — | — | |
| SCHEMBL25683609 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719608-A1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AS THERAPEUTIC COMPOUNDS FOR HIV | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250042926-A1 | THERAPEUTIC COMPOUNDS FOR HIV | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2024249592-A1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AS THERAPEUTIC COMPOUNDS FOR HIV | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102239-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |